BioSpace News Archive

Virogentics, Inc. a wholly owned subsidiary of Enzolytics, Inc., a drug development biotech company, announced the receipt of an export permit for the delivery of the treatments to be administered to the volunteer HIV/AIDS patients at the HEAL Africa Hospitals, GOMA, PRC and Panzi Hospital, Bukavu, DRC.

Celmatix Inc. and Aché Laboratórios, a leading Brazilian pharmaceutical company, announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women’s Health indications.

C2N Diagnostics, a leader in advanced brain health diagnostics, says new research posted in the online version of Annals of Clinical and Translational Neurology affirms the clinical utility of its PrecivityAD® blood test, which healthcare providers use to help diagnosis Alzheimer’s disease.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, part of the Intermountain Health system, will begin providing oncology test results that allow access to the ComboMATCH trials.

Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Treace Medical Concepts, Inc., a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus through its Lapiplasty® 3D Bunion Correction™ Procedure, reported financial results for the second quarter ended June 30, 2023.

Standard BioTools Inc. reported financial results for the second quarter ended June 30, 2023.

eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult to treat cancers, announced that the Company will report second quarter 2023 financial results on Monday, August 14, 2023, after market close.

Voyager Therapeutics, Inc., a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, has entered into an employment agreement with Beth Shafer, Ph.D., M.A., M.Phil. that, among other things, provides for the grant to Dr. Shafer of a non-qualified stock option and restricted stock units as an inducement material to Dr. Shafer’s entering into employment with Voyager as Voyager’s Chief Business Officer.